Abstract: A phage dispensing system comprises a user interface, a phage treatment computing system, a phage laboratory, and a phage dispensing apparatus, including a dispensing kiosk. The user interface allows a treating physician to request testing of a patient sample by the phage laboratory to identify a phage mixture treatment. The phage computing system arranges shipping of the sample and provision of the identified phage mixture treatment to a dispensing apparatus located near the patient. The dispensing apparatus has a stock of phage vials which are used to prepare and dispense doses of the identified phage mixture treatment.

Abstract: A phage dispensing system comprises a user interface, a phage treatment computing system, a phage laboratory, and a phage dispensing apparatus, including a dispensing kiosk. The user interface allows a treating physician to request testing of a patient sample by the phage laboratory to identify a phage mixture treatment. The phage computing system arranges shipping of the sample and provision of the identified phage mixture treatment to a dispensing apparatus located near the patient. The dispensing apparatus has a stock of phage vials which are used to prepare and dispense doses of the identified phage mixture treatment.

Abstract: A method of recovering viable phage from, for example, a crude phage preparation such as a lysate resulting from amplification of phage in bacterial cell culture is disclosed. The method may be “universal”; that is, applicable to the purification of a broad range of phage species and strains. The phage product resulting from the method may have an acceptably low endotoxin titer (e.g. less than 500 EU/ml) and sufficiently high phage titer (e.g. >1×109 PFU/ml) for use in therapeutic applications.

Abstract: A transdermal membrane comprising a non-infectious icosahedral phage vaccine displaying an antigen is described wherein the membrane is stable at room temperature for greater than 3 months and uses thereof to vaccinate a subject against the antigen.

Abstract: The invention relates to the production of biopharmaceuticals and, more particularly, to a novel method of monitoring for contamination of such products with components of any host cells used or involved in the manufacturing process. The method comprises a step of determining the presence in a biopharmaceutical (e.g. a therapeutic phage composition) of a ribosomal subunit protein unique to bacteria (or protein fragments thereof) or a nucleic acid molecule comprising a nucleotide sequence derived from a gene encoding a ribosomal subunit protein unique to bacteria.

Abstract: A simple method and kit for preserving clinical specimens and other biological samples, particularly for the purpose of preserving the concentration of bacteriophage and/or bacteria present in a sample, is described. The method involves rapidly lowering the temperature of the sample (e.g. freezing) to a temperature of ?50° C. or lower (especially about ?78° C.) in the presence of a suitable cryoprotectant (e.g. 20% glycerol). In one application, the method is used with clinical samples (e.g. urine) taken from a patient undergoing phage therapy for a bacterial infection, wherein the method permits the samples to be transported and/or stored following collection such that the viability of any phage and/or bacteria present is maintained while also inhibiting potential interactions between the phage and bacteria. After thawing of the samples, the samples may be analyzed for phage and/or bacterial concentration to provide information on the effectiveness of the phage therapy.

Abstract: Methods and systems for pattern search and analysis to identify and select therapeutic molecules that can be used to treat bacterial infections or contaminations. Examples include methods and systems for pattern search and analysis to identify and select bacteriophage based on comparison of the genomes of a query bacterium and/or a query phage strain to a therapeutic molecule-host training set of bacterial strains and/or phage strains in which the phage strains (or other therapeutic molecules) have been shown to have the capacity to act as an antibacterial agent by either killing, replicating in, lysing and/or inhibiting the growth of the bacterial strains in the training set. Therapeutic compositions, including phage, identified using the methods described herein can then be used to treat bacterial infections in a subject and/or contamination in the environment.

Abstract: A phage dispensing system comprises a user interface, a phage treatment computing system, a phage laboratory, and a phage dispensing apparatus, including a dispensing kiosk. The user interface allows a treating physician to request testing of a patient sample by the phage laboratory to identify a phage mixture treatment. The phage computing system arranges shipping of the sample and provision of the identified phage mixture treatment to a dispensing apparatus located near the patient. The dispensing apparatus has a stock of phage vials which are used to prepare and dispense doses of the identified phage mixture treatment.

Abstract: The invention is related to a non-biotinylated bacteriophage that comprises a nucleic acid sequence encoding a biotinylation domain, a complex that comprises a biotinylated bacteriophage and a biotin-specific ligand conjugated bioconjugate, and a method of detecting a bacterial cell in a sample comprising contacting the sample with a non-biotinylated bacteriophage that comprises a nucleic acid sequence encoding a biotinylation domain, wherein the bacteriophage is specific to the bacterial cell.

Abstract: The present invention is directed to recombinant vaccines, based on a phage vector system, which enhance immunological response and allow rapid construction and deployment of vaccines.

Abstract: This disclosure provides methods of selecting a therapeutic bacteriophage and identifying bacteria in a sample. The sample may be obtained from a plant or animal subject diagnosed with a disease caused by a bacterial infection or an object suspected of being exposed to a bacterium. The activity of reporter molecules, either encoded in the bacteriophage genome or added during sample analysis, is used to determine whether bacteriophages are capable of infecting assayed bacteria. Also provided are methods of selecting a bacteriophage for potential use in treating of bacterial infection, based upon the selectivity of the bacteriophage host range for the bacterium. The bacteriophages or bacteria may be immobilized in an array, such that multiple bacteriophages and/or bacteria may be assayed. Kits are also provided.

Abstract: The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.

Abstract: The invention relates to a biomolecular complex comprising a target biomolecule; a phage having a phage-expressed binding protein that can bind to the target biomolecule or having joined thereto a linked or un-linked protein or nucleic acid that can bind to the target biomolecule, wherein the phage-expressed binding protein or the linked or unlinked protein or nucleic acid is bound to the target biomolecule to provide a bound phage; and a host bacterial cell that is a host for the phage under conditions that permit the bound phage to infect the host.

Abstract: The invention relates to a biomolecular complex comprising a target biomolecule; a phage having a phage-expressed binding protein that can bind to the target biomolecule or having joined thereto a linked or un-linked protein or nucleic acid that can bind to the target biomolecule, wherein the phage-expressed binding protein or the linked or unlinked protein or nucleic acid is bound to the target biomolecule to provide a bound phage; and a host bacterial cell that is a host for the phage under conditions that permit the bound phage to infect the host.